Presbia — Investor Presentation (September 2017)
16 slides from Presbia's investor presentation, Sep 8, 2017
Slide 1: September 2017 Investor Presentation
September 2017 CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use.
Slide 2: Disclosure
Disclosure To the extent statements contained in this presentation are not descriptions of historical facts regarding Presbia PLC and its subsidiaries (collectively “Presbia,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward
Slide 3: Presbia Restores Near Vision
Presbia Restores Near Vision Presbia has developed a solution for presbyopia, an age related condition affecting people from approximately 40 years of age, to help restore near vision Safe, effective and minimally invasive surgical procedure Currently marketed in certain markets outside the United S
Slide 4: Large, Underserved and Growing Commercial/Market Opportunity
Large, Underserved and Growing Commercial/Market Opportunity 1.9 Billion Presbyopes Source: 2016 Market Scope Refractive Surgery Report (millions)
Slide 5: The Presbia Flexivue Microlens
The Presbia Flexivue MicrolensTM The Presbia Flexivue Microlens™ is a best in class treatment option for presbyopia A powered corneal inlay is implanted in the non-dominant eye, with minimal impact to binocular distance vision Presbia has unique competitive advantages A refractive lens like reading
Slide 6: The Presbia Procedure
True “Microlens” with 3.2 mm diameter and edge thickness of 0.015 mm Hydrophilic acrylic material similar to that used in IOLs for > 20 years Invisible to the naked eye once implanted Can be done concurrently or pre/post LASIK or cataract surgery Offered in a wide range of powers ranging from +1.5 d
Slide 7: Competitive Landscape
Competitive Landscape AcuFocus - KAMRA Non-powered “disc” implanted in the non-dominant eye Utilizes the “pinhole effect” to focus light to enhance near vision The disc is visible to naked eye in light colored eyes Difficult for patient in low light environments Obstructs the view of the retina in d
Slide 8: The Physician Appeal
The Physician Appeal LASIK Cataract Presbyopia No established surgical market for the 40–60 year old patient pool 20s 30s 40s 50s 60s 70s 80s ? ? ? Presbia provides ophthalmologist with an exciting new option to treat patients with presbyopia Incremental revenue driver No capital expenditure require
Slide 9: Commercial Opportunity - LASIK as a Market Benchmark
Commercial Opportunity - LASIK as a Market Benchmark * Market Scope, 2014 Corneal inlay has the potential to impact the Presbyopia market similar to LASIK’s impact on vision correction in younger patients Presbia Flexivue Microlens™ requires a less invasive procedure About 1.6x more people suffer fr
Slide 10: Focused Commercial Strategy
Focused Commercial Strategy Build global KOL acceptance carrying momentum into US commercial launch Registered to commercialize in 42 different countries Clinics implanting in South Korea, Germany, Ireland, UK, Netherlands, Australia/NZ, and Canada Gain FDA approval and begin marketing in the United
Slide 11: Compelling Results
Compelling Results Subjects can perform almost all near vision tasks without glasses For example, an improvement from reading a subhead in the newspaper (12pt font) to reading the content label (4pt font) on a medicine bottle
Slide 12: Improvement in Uncorrected Near Visual Acuity in Operated Eyes
Improvement in Uncorrected Near Visual Acuity in Operated Eyes ~20/80 ~20/25 +5 line improvement in Uncorrected Near Visual Acuity in treated eyes compared to preoperative visual acuity
Slide 13: No change in Binocular Uncorrected Distance Visual Acuity
No change in Binocular Uncorrected Distance Visual Acuity 20/16 to 20/25 ≥ 96% of Subjects with Uncorrected Distance Visual Acuity Preoperatively and at Month 18 between 20/16 and 20/25
Slide 14: US Registration Timeline
US Registration Timeline Complete 24 Month follow up for ALL subjects Complete 24 Month follow up for 300 subjects US PMA Submit PMA Anticipate Approval Complete documents for PMA Module 4 (study report, labeling) Q4 2017 Q1 2018 Q2 2018 Q3/4 2018
Slide 15: Business Highlights
Business Highlights 118 million presbyopes in the U.S.; 1.9 billion presbyopes worldwide (2016)* Large, Underserved Presbyopia Opportunity Best-in-Class Microlens Technology Strong Leadership and Compelling Business Model Refractive corneal inlay restores reading vision—on average 5 lines of improve
Slide 16: CAUTION - Investigational Device
CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use.